secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0000950170-25-110374
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health receives two INDs for Entolimod from Statera for ARS and advanced cancers
--------------------------------------------------------------------------------

- Completed transfer of two INDs from Statera Biopharma for lead candidate Entolimod.
- INDs cover acute radiation syndrome (ARS-H and ARS-GI sub-syndromes) and advanced cancers.
- Enables formal FDA engagement on regulatory pathway for ARS; near-term focus on ARS as first indication.
- Also enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-treatment conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025110374/0000950170-25-110374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025110374/tivc-20250820.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-110374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer